Cargando…
Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options
The residual risk of patients surviving until 1 year after acute coronary syndromes (ACS) is still high, despite secondary prevention. The cornerstone of treatment of patients with ACS is dual antiplatelet therapy (DAPT) consisting of low-dose aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel or...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bohn Stafleu van Loghum
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724500/ https://www.ncbi.nlm.nih.gov/pubmed/34357557 http://dx.doi.org/10.1007/s12471-021-01604-4 |